Antidepressant pharmacotherapy in adults with type 2 diabetes: rates and predictors of initial response

Ryan J Anderson, Britt M Gott, Gregory S Sayuk, Kenneth E Freedland, Patrick J Lustman, Ryan J Anderson, Britt M Gott, Gregory S Sayuk, Kenneth E Freedland, Patrick J Lustman

Abstract

OBJECTIVE Initial treatment with antidepressant medication is insufficiently effective in some patients with type 2 diabetes, and factors predicting treatment outcome are poorly understood. RESEARCH DESIGN AND METHODS Aggregate data from two published trials were analyzed to determine the rates and predictors of response to antidepressant pharmacotherapy in adults with type 2 diabetes using conventional markers of initial treatment outcome (improvement, response, partial remission, and remission). Three hundred eighty-seven patients who received up to 16 weeks of open-label, acute-phase treatment using bupropion (n = 93) or sertraline (n = 294) were studied. Logistic regression was used to identify predictors of poor treatment outcome. Candidate predictors included age, race, sex, initial Beck Depression Inventory (iBDI) score, treatment received (sertraline or bupropion), family history of depression, extant diabetes complications (eDC), and A1C level. RESULTS Of 387 patients initiated on treatment, 330 (85.3%) met criteria for improvement, 232 (59.9%) for response, 207 (53.5%) for partial remission, and 179 (46.3%) for full remission. Significant independent predictors of poor outcome included eDC (for no improvement); sertraline treatment, eDC, and younger age (for nonresponse); sertraline treatment, eDC, and higher iBDI (for failure to partially remit); and younger age and higher iBDI (for failure to fully remit). Higher pain scores predicted three of the four markers of poor outcome in the subset with pain data. CONCLUSIONS In patients with type 2 diabetes, poor initial response to antidepressant medication is predicted by multiple factors. Auxiliary treatment of pain and impairment may be required to achieve better outcomes.

Figures

Figure 1
Figure 1
Positive predictive value of poor depression treatment outcome (nonremission [■] or nonimprovement []) by cumulative number of the three features most often found to be significant in the regression analyses (presence of any diabetes complications, younger age [<50 years], and higher iBDI score [>23]). Patients without any of these features had a 23% chance of not remitting and an 8% chance of not improving. Presence of all three features had a positive predictive value of 68% for nonremission and 17% for nonimprovement.

References

    1. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001;24:1069–1078
    1. Lustman PJ, Griffith LS, Clouse RE: Depression in adults with diabetes: results of a 5-year follow-up study. Diabetes Care 1988;11:605–612
    1. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM: Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000;23:434–442
    1. de Groot M, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ: Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001;63:619–630
    1. Zhang X, Norris SL, Gregg EW, Cheng YJ, Beckles G, Kahn HS: Depressive symptoms and mortality among persons with and without diabetes. Am J Epidemiol 2005;161:652–660
    1. Lustman PJ, Griffith LS, Clouse RE, Freedland KE, Eisen SA, Rubin EH, Carney RM, McGill JB: Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom Med 1997;59:241–250
    1. Lustman PJ, Freedland KE, Griffith LS, Clouse RE: Fluoxetine for depression in diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Care 2000;23:618–623
    1. Lustman PJ, Clouse RE, Nix BD, Freedland KE, Rubin EH, McGill JB, Williams MM, Gelenberg AJ, Ciechanowski PS, Hirsch IB: Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006;63:521–529
    1. Lustman PJ, Griffith LS, Freedland KE, Kissel SS, Clouse RE: Cognitive behavior therapy for depression in type 2 diabetes: a randomized controlled trial. Ann Intern Med 1998;129:613–621
    1. Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T: The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004;61:1042–1049
    1. Esposito K, Goodnick P: Predictors of response in depression. Psychiatr Clin North Am 2003;26:353–365
    1. Lustman PJ, Freedland KE, Griffith LS, Clouse RE: Predicting response to cognitive behavior therapy of depression in type 2 diabetes. Gen Hosp Psychiatry 1998;20:302–306
    1. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28–40
    1. Lustman PJ, Williams MM, Sayuk GS, Nix BD, Clouse RE: Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. Diabetes Care 2007;30:459–466
    1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision. Washington, D.C., American Psychiatric Association, 2000.
    1. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62
    1. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM: American Diabetes Association. Tests of glycemia in diabetes. Diabetes Care 2004;27:S91–S93
    1. Stewart AL, Hays RD, Ware JE, Jr: The MOS short-form general health survey: reliability and validity in a patient population. Med Care 1988;26:724–735
    1. Riso LP, Thase ME, Howland RH, Friedman ES, Simons AD, Tu XM: A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. J Affect Disord 1997;43:131–142
    1. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF: Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:1841–1853
    1. Kilts CD, Wade AG, Andersen HF, Schlaepfer TE: Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 2009;10:927–936
    1. Kovacs M, Mukerji P, Drash A, Iyengar S: Biomedical and psychiatric risk factors for retinopathy among children with IDDM. Diabetes Care 1995;18:1592–1599
    1. Williams MM, Clouse RE, Nix BD, Rubin EH, Sayuk GS, McGill JB, Gelenberg AJ, Ciechanowski PS, Hirsch IB, Lustman PJ: Efficacy of sertraline in prevention of depression recurrence in older versus younger adults with diabetes. Diabetes Care 2007;30:801–806
    1. Bair MJ, Robinson RL, Katon W, Kroenke K: Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433–2445

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa